Industry Standards Group, Align Biopharma, Expands to 23 Members
July 13 2017 - 7:03AM
Business Wire
Leading companies join forces to develop and
implement new technology standards
Align BiopharmaTM, a life sciences industry technology standards
group, today introduced 14 leading biopharma companies and
technology and service providers as new members. In six months
since it was formed, Align Biopharma has become a fast-growing
influence in the industry to create and implement open technology
standards. The group now includes a total of 23 members dedicated
to making it easier for healthcare professionals (HCPs) to connect
digitally with life sciences companies.
“Technology standards will solve a significant business problem
across the industry by helping get information to stakeholders when
and where they need it,” said Ed Kloskowski, VP, head of commercial
IT at Shire, one of Align Biopharma’s newest members. “At Shire, we
are focused on meeting the needs of underserved patient
communities. Joining forces in Align Biopharma to work together to
harmonize digital engagement in a way that will ultimately help
patients is one more path to serving our patient community.”
In addition to life sciences companies as members, Align
Biopharma now includes technology providers, Adobe, Exostar, Gigya,
Janrain, and Okta, and service providers Accenture, Cognizant,
Deloitte, and Mavens. These leading companies are helping to define
and review Align Biopharma’s open technology standards to ensure
broad industry adoption.
“Align Biopharma has seen an overwhelming response from across
the industry,” said Henry Levy, president of Align Biopharma. “It’s
clear there is a significant opportunity to improve the digital
experience for healthcare professionals. We’re attracting the best
experts that are shaping the standards to simplify how HCPs get the
important treatment information they need.”
Align Biopharma’s first standard is for identity management.
Expected available in summer 2017, the standard defines the
technical requirements for solutions that provide a single sign-on
service for HCPs. Align Biopharma has also begun development of its
second standard for consent and preference management, which will
enable consistency in how healthcare professionals specify
communication preferences with each life sciences company. Align
Biopharma expects to post its consent and preference management
standard for public review and input later this year.
What New Align Biopharma Members Are Saying:
“Accenture is pleased to be a member of Align Biopharma in the
quest to create technology standards that benefit the entire
healthcare community and accelerate treatments to patients who need
them,” said Kevin Julian, senior managing director, Accenture Life
Sciences North America.
“Adobe is pleased to join Align Biopharma,” said Thomas Swanson,
head of industry strategy & marketing, healthcare at Adobe.
“Open technology standards development provides the industry
standardization it can rely upon, enabling digital technology to
help transform the healthcare experience.”
“As life sciences companies focus on digital transformation,
technology standards are important to enable efficient information
sharing across systems and platforms,” said Bhaskar Sambasivan,
senior vice president and global head of life sciences markets at
Cognizant. “We look forward to contributing to this important
industry initiative that will make it easier for life sciences
companies to collaborate with healthcare professionals and help
improve patient care.”
“The U.S. healthcare system is complex, but by creating and
implementing new standards, Align Biopharma can help advance
digital capabilities for healthcare professionals,” said David
Rosner, principal and digital life sciences leader, Deloitte
Consulting LLP. “These new technology standards can not only
benefit providers, but also patients by offering quicker access to
medical records, and providing doctors more time for patient
care.”
“The benefits of Align Biopharma’s standards will extend beyond
healthcare providers and pharmaceutical companies to patients,
providing them a clear and uniform process to give consent for use
of their healthcare data, while protecting their privacy and
securing their personal information,” said Eyal Magen, chief
strategy officer of Gigya. “Gigya is ready to make a significant
contribution to this important effort.”
“Our excitement around Align Biopharma is rooted in our passion
to innovate and collaborate and share those innovations with the
broader industry,” said Jim Kaskade, CEO of Janrain. “We’re eager
to come together with other leading companies and contribute our
learnings and experiences as part of Align Biopharma. We are
committed to not only advancing the HCP experience, but also
improving patients’ experiences and our client organizations’
experiences.”
“Align Biopharma’s technology standards embody a goal tightly
aligned with Mavens’ mission to combine best-in-class cloud
technologies to build software solutions that connect people to
cures and elevate the global healthcare industry,” said Prasad
Kanumury, CEO of Mavens. “We are excited to be a part of this
important work, simplifying the lives of healthcare professionals,
and freeing time to focus on patients.”
“An identity standard for HCPs will pave the way to reducing the
number of accounts and passwords a practitioner must remember, and
put their valuable time where it belongs – with patients, not with
password resets,” said Chuck Fontana, VP of business development at
Okta. “As an Align Biopharma member, we look forward to continuing
to help healthcare providers adopt any technology without
sacrificing security or user experience.”
Additional Information
Connect with Align Biopharma on LinkedIn:
linkedin.com/company/align-biopharmaFollow @alignbiopharma on
Twitter: twitter.com/alignbiopharma
About Align Biopharma
Align Biopharma is an industry standards group founded by top
global pharmaceutical companies and Veeva Systems. The group
includes more than 20 leading pharmaceutical, technology, service
provider companies that are dedicated to making it faster and
easier for healthcare professionals to connect with the life
sciences industry. For more information, visit
AlignBiopharma.org.
Please see www.deloitte.com/us/about for a detailed description
of Deloitte’s legal structure.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170713005358/en/
for Align BiopharmaBarbadora InkLisa Barbadora,
610-420-3413lbarbadora@barbadoraink.com
Veeva Systems (NYSE:VEEV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Veeva Systems (NYSE:VEEV)
Historical Stock Chart
From Apr 2023 to Apr 2024